Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer

Published on January 6, 2009 Archived on February 25, 2021   54 min

Other Talks in the Category: Pharmaceutical Sciences

Hide

Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer

Embed in course/own notes